Laboratory Co. of America (LH) Stock Forecast, Price & News

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Laboratory Co. of America in the last twelve months. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LH shares.
View LH analyst ratings or view top-rated stocks.

10 brokerages have issued 12 month price objectives for Laboratory Co. of America's stock. Their LH share price forecasts range from $210.00 to $270.00. On average, they predict the company's stock price to reach $244.55 in the next twelve months. This suggests a possible upside of 17.3% from the stock's current price.
View analysts price targets for LH or view top-rated stocks among Wall Street analysts.

Laboratory Co. of America's stock was trading at $235.48 on January 1st, 2023. Since then, LH shares have decreased by 11.5% and is now trading at $208.42.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our LH earnings forecast.

Laboratory Co. of America Holdings (NYSE:LH) posted its earnings results on Thursday, July, 27th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.47 by $0.05. The medical research company had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.77 billion. Laboratory Co. of America had a trailing twelve-month return on equity of 14.62% and a net margin of 5.89%. Laboratory Co. of America's revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the firm earned $4.96 earnings per share.
Read the conference call transcript.

Laboratory Co. of America announced a quarterly dividend on Thursday, July 13th. Stockholders of record on Tuesday, August 8th will be paid a dividend of $0.72 per share on Friday, September 8th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.38%. The ex-dividend date of this dividend is Monday, August 7th.
Read our dividend analysis for LH.

ETFs with the largest weight of Laboratory Co. of America (NYSE:LH) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), Cambiar Aggressive Value ETF (CAMX), Global X Telemedicine & Digital Health ETF (EDOC), iShares U.S. Healthcare Providers ETF (IHF), VictoryShares THB Mid Cap ESG ETF (MDCP), BlackRock Large Cap Value ETF (BLCV), Strategas Global Policy Opportunities ETF (SAGP) and Thrivent Small-Mid Cap ESG ETF (TSME).

Laboratory Co. of America (NYSE:LH) pays an annual dividend of $2.88 per share and currently has a dividend yield of 1.40%. The dividend payout ratio is 31.07%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LH will have a dividend payout ratio of 19.59% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LH.

Laboratory Co. of America updated its FY 2026 earnings guidance on Friday, September, 15th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $14.00B-.

143 employees have rated Laboratory Co. of America Chief Executive Officer Adam Schechter on Glassdoor.com. Adam Schechter has an approval rating of 73% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Laboratory Co. of America investors own include Gilead Sciences (GILD), Micron Technology (MU), Intel (INTC), Pfizer (PFE), Johnson & Johnson (JNJ), NVIDIA (NVDA), Abbott Laboratories (abt), AbbVie (ABBV), Alibaba Group (BABA) and Amgen (AMGN).

Laboratory Co. of America trades on the New York Stock Exchange (NYSE) under the ticker symbol "LH."

Laboratory Co. of America's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (14.34%), State Street Corp (4.44%), Geode Capital Management LLC (2.12%), Lazard Asset Management LLC (1.95%), Dimensional Fund Advisors LP (1.65%) and Northern Trust Corp (1.13%). Insiders that own company stock include Amy B Summy, Brian J Caveney, Der Vaart Sandra D Van, Dwight Gary Gilliland, Glenn A Eisenberg, Jean-Luc Belingard, Kerrii B Anderson, Mark S Schroeder, Paul R Kirchgraber, Peter J Wilkinson, Peter M Neupert and R Sanders Williams.
View institutional ownership trends.

Shares of LH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LH stock can currently be purchased for approximately $208.42.

Laboratory Co. of America (NYSE:LH) has a market capitalization of $18.47 billion and generates $14.88 billion in revenue each year. The medical research company earns $1.28 billion in net income (profit) each year or $9.27 on an earnings per share basis.

The company employs 80,000 workers across the globe.

Laboratory Co. of America's mailing address is 358 South Main Street, BURLINGTON NC, 27215. The official website for the company is www.labcorp.com. The medical research company can be reached via phone at (336) 229-1127, via email at investor@labcorp.com, or via fax at 336-513-4510.